Boehringer Cashes In Co-Marketed Empagliflozin Brands Ahead Of India Patent Expiry

GLP-1 Generics Coming In 2026

 
• By Vibha Ravi
  
A Business Deal
Torrent And Boehringer Ingelheim Work Out Deal For Anti-Diabetes Brands In India (Shutterstock)

More from India

More from Market Access